Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast cancer.

Umberto Veronesi1, Peter Boyle, Aron Goldhirsch

  • 1European Institute of Oncology, Milan, Italy. umberto.veronesi@ieo.it

Lancet (London, England)
|May 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Cancer·2025
Same author

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].

Breast (Edinburgh, Scotland)·2025
Same author

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.

Breast (Edinburgh, Scotland)·2025
Same author

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer.

Breast (Edinburgh, Scotland)·2024
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

This study reviews recent breast cancer research, highlighting lifestyle factors like early childbirth and tamoxifen use that reduce risk. It also discusses new diagnostic and treatment approaches for breast cancer.

Area of Science:

  • Oncology
  • Public Health
  • Genetics

Background:

  • Breast cancer is a significant global health concern.
  • Recent advancements have improved understanding and management.
  • Key risk factors and diagnostic methods are evolving.

Purpose of the Study:

  • To summarize key findings in breast cancer research from the past five years.
  • To highlight updated information on risk reduction, diagnosis, and treatment.
  • To discuss emerging theories and therapeutic strategies.

Main Methods:

  • Literature review of studies published in the last 5 years.
  • Analysis of epidemiological data on risk factors.
  • Evaluation of advancements in imaging and therapeutic modalities.

Related Experiment Videos

Main Results:

  • Factors like early first birth, higher parity, and tamoxifen use correlate with reduced long-term breast cancer risk.
  • Ductal carcinoma in situ (DCIS) may be renamed to ductal intraepithelial neoplasia (DIN).
  • Mammography and ultrasonography remain effective for specific breast densities; MRI and other advanced techniques show promise for subgroups.

Conclusions:

  • Emerging research supports the progenitor/stem cell theory for targeted cancer treatment.
  • Aromatase inhibitors are increasingly used alongside tamoxifen for endocrine-responsive breast cancer.
  • Molecular target assessment and novel therapies like tyrosine-kinase inhibitors are crucial for future breast cancer management.